Has Michael Flowers, MD received payments from drug or device companies?

Yes. Drug and device makers reported $820 in general payments to Michael Flowers, MD across 32 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Flowers, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Flowers, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Flowers, MD

Internal Medicine · Knoxville, TNNPI 1669409645

Payments from drug & device makers

$820in general payments, 2019–2025

Across 32 payments — averaging $25.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Pfizer$335
Mylan Specialty L.p.$149
AstraZeneca$131
Cumberland Pharmaceuticals, Inc.$83
E.r. Squibb & Sons, L.L.C.$37
Acadia Pharmaceuticals Inc$33
plus $53 from 3 others

What the payments were for

Food & beverage$80098%
Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Pfizer	19	$335
Mylan Specialty L.p.	1	$149
AstraZeneca(2 entities)	4	$131
Cumberland Pharmaceuticals, Inc.	1	$83
E.r. Squibb & Sons, L.L.C.	2	$37
Acadia Pharmaceuticals Inc	2	$33
CSL Behring	1	$20
AbbVie	1	$19
UCB, Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Yupelri$149

How this compares

$820 in reported general payments places this provider in the 65th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee →

Medicare billing

Part B allowed, 2024

$100,787

Medicare patients

370

Services billed

1,175

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	18	$10,563
Cefdinir	33	$384
Bumetanide	11	$328
Diltiazem 24hr Er (Cd)Diltiazem Hcl	12	$327
Atorvastatin Calcium	35	$315
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav	21	$264
Metoprolol Tartrate	54	$248
ClopidogrelClopidogrel Bisulfate	39	$248
Hydralazine Hcl	19	$224
Valsartan	11	$185
Furosemide	49	$182
Metoprolol Succinate	16	$174
Amlodipine Besylate	38	$148
Potassium Chloride	12	$99
Carvedilol	21	$78

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
PfizerEliquis	$335	$10,56318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Knoxville

Amanda Moore MillerKnoxville$2.3M
George NewmanKnoxville$682K
Dennis DeruelleKnoxville$263K
Lewis HagoodKnoxville$143K
Johnny AltawilKnoxville$23K
Mark McKenzieChattanooga$11.9M
Bernard GrunstraBristol$6.4M
Jewel WhiteKingsport$5.7M
Judith WhiteKingsport$5.6M
Obadias MarquezOoltewah$2.8M

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →